PREP | PEP
PrEP (Pre-Exposure Prophylaxis) is daily antiretroviral medication taken to reduce the risk of HIV infection in HIV-negative individuals. In July 2012, the US Food and Drug Administration approved the use of Truvada (TDF/FTC) for use as PrEP in HIV prevention in sexually active HIV-negative individuals.
- Daily PrEP reduces the risk of getting HIV from sex by more than 90%.
- PrEP reduces the risk by more than 70% among people who inject drugs.
- PrEP is used in conjunction with condoms and other prevention methods to reduce the risk of infection.
Download the PrEP brochure. (1.4 MB PDF)
Cost assistance for PrEP/PEP
Gilead offers the Truvada® for PrEP medication assistance program that assists eligible HIV-negative adults in the United States who need assistance paying for PrEP (pre-exposure prophylaxis).
Call the PrEP Line at 904-253-1448.
PEP (Post-Exposure Prophylaxis) involves taking antiretroviral medications as soon as possible after a potential exposure to HIV to reduce the likelihood of HIV infection.
- There are two types of PEP: 1) occupational PEP, or an exposure that happens in the workplace (such as a needle stick in a healthcare setting), and 2) non-occupational PEP (nPEP), or when someone is potentially exposed to HIV through sexual intercourse or injection drug use.
- To be effective, PEP must begin with 72 hours of exposure and consists of 2-3 antiretroviral medications that must be taken for 28 days.
- Starting PEP after a potential exposure does not guarantee that someone exposed to HIV will not become infected.